REVIEW ARTICLE

Nanomedicine in Cancer Treatment: Harnessing Nanotechnology for Targeted Drug Delivery and Advanced Imaging Techniques

Amin S S*, Jogdand S D

Institutional Name: Datta Meghe Institute of Higher Education and Research, Wardha

Received: 21st Oct 2024; Revised: 3rd Nov, 2024; Accepted: 25th Nov, 2024; Available Online: 25th Dec, 2024

ABSTRACT

Nanomedicine has transformed cancer treatment by utilizing nanotechnology to create more precise, targeted, and less toxic therapies. Traditional methods like chemotherapy and radiation often lack specificity, causing side effects and limiting effectiveness. Nanoparticles, sized between 1 and 100 nanometres, enable targeted drug delivery, minimizing damage to healthy tissues. Through the improved Permeability along with Retention (EPR) effect, nanoparticles accumulate in tumours due to leaking vasculature. Active targeting, using ligands like antibodies, enhances precision by interacting with specific cancer receptors, such as HER2 in breast cancer. Doxil is a liposomal preparation of doxorubicin that improves progression-free survival in ovarian cancer patients by reducing cardiotoxicity. Nanoparticles also enhance cancer imaging, improving the resolution of techniques like MRI, CT, and PET. Gold nanoparticles and iron oxide nanoparticles act as contrast agents, aiding early tumor detection. Furthermore, Theranostic nanoparticles integrate therapeutic and diagnostic functions, facilitating real-time assessment of treatment efficacy for enhanced tailored care. Despite its potential, Nanomedicine faces challenges like toxicity, immune clearance, and scalability. Nanoparticles may be identified and eliminated via the reticuloendothelial system (RES), reducing efficacy. However, solutions like PEGylation and biodegradable nanoparticles are addressing these barriers. The global Nanomedicine marketplace, valued at $150 billion in 2021, is anticipated to expand at a compound annual growth rate (CAGR) of 11.9% complete 2030, underscoring the expanding role of nanotechnology in cancer treatment.

Keywords: *Nanomedicine, Targeted Drug Delivery, Nanoparticles, Imaging Techniques*

How to cite this article: Amin S S, Jogdand S D. Nanomedicine in Cancer Treatment: Harnessing Nanotechnology for Targeted Drug Delivery and Advanced Imaging Techniques. International Journal of Drug Delivery Technology. 2024;14(4):2534-40. doi: 10.25258/ijddt.14.4.75

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Background on Cancer Treatment

Cancer continues to be a significant global health concern, resulting in millions of new cases and fatalities annually. In 2020, over 19 The World Health Organization (WHO) reports over one million new cancer diagnoses and approximately ten million cancer-related deaths. The greatest general types include lung, breast, prostate, stomach and colorectal cancers.[1,3] while treatment has improved significantly over the past decades, traditional methods—such as chemotherapy, radiation therapy, and surgery continue to be the mainstay of cancer care. Unfortunately, these approaches come with substantial limitations that impact their effectiveness the patient's standard of living.[2]

Chemotherapy

Chemotherapy, commonly used treatments, works by targeting rapidly dividing cells. While effective in killing cancer cells, It also impacts healthy cells that proliferate rapidly, swiftly, like ones found in the marrow of the bone and and gastrointestinal tract.[4] This lack of specificity results in severe side effects like hair loss, fatigue, nausea, and increased susceptibility to infections[5]. In some aggressive cancers, chemotherapy can only achieve partial remission, and over time, many tumours develop resistance to these drugs.[6] According to the American Cancer Society, success rates for complete remission can range between 50-60% for certain malignancies, including non-Hodgkin lymphoma and leukemia.[7] The use of radiation utilizes high-energy waves or particles to inflict injury to the DNA of cancer cells, thereby constraining their growth and division.[8] It is commonly used alongside surgery and chemotherapy.[9] While effective for localized tumors, radiation also has risks. It can damage surrounding healthy tissues, leading to complications such as fibrosis or even secondary cancers in the long term.[10] Approximately fifty percent of all cancer patients have radiation therapy at some stage of their treatment, underscoring its importance but also its risks.[11]

Surgery

The objective of surgery is to excise the tumour physically often along with adjacent tissue to guarantee total removal of the cancerous cell. While operation remains an essential treatment option for many solid tumours, it is not always feasible, especially for cancers that have metastasized or are located in difficult-to-reach areas. Furthermore, surgery carries risks such as infection, bleeding, and pain, and it may require a prolonged recovery period.[10]

Despite the life-saving potential of these traditional treatments, their limitations—such as toxicity, lack of specificity, and the development of resistance—highlight the urgent need for more precise, effective, and patient-

**Author for Correspondence: shantanuamin95@gmail.com*

Figure 1 Reasons for Drug Targeting



Figure 2 Nanoparticles in Imaging-Guided PTT for Colorectal Cancer Therapy

friendly therapies. This has led to the exploration of alternative strategies, such as targeted therapies, immunotherapy, and nanomedicine, which aim to address the shortcomings of conventional cancer treatment.[12]

Introduction to Nanomedicine

Nanomedicine is an emerging field that applies nanotechnology principles to the diagnosis, treatment, and monitoring of diseases, particularly cancer[13] Nanotechnology involves manipulating materials at an exceptionally diminutive size, generally ranging from 1 to 100 nanometers about 100,000 times thinner than the width of an individual's hair. At the nanoscale, materials can have distinctive physical, chemical, and biological features that render them highly useful in medical applications, especially for delivering drugs and enhancing imaging in cancer treatment.[14] Targeted drug delivery in nanomedicine demonstrates significant potential, particularly in cancer therapy. In contrast to conventional chemotherapy, which adversely affects both malignant and healthy cells, nanoparticles can target tumor tissues specifically. This occurs through the enhanced permeability and retention (EPR) effect, allowing nanoparticles to penetrate tumors and deliver drugs directly to cancer cells, thus reducing damage to healthy tissues.[16] Moreover, nanoparticles can be modified using certain molecules, such as antibodies, that selectively target and attach to cancer cells, hence enhancing the accuracy of medication delivery.[17] Nanomedicine is

Table 1: Comparison of Nanoparticles for Drug Delivery and Imaging in Cancer Treatment[23-27]

Nanoparticle Type	Size (nm)	Application	Advantages	Limitations	Examples
Liposomes	50-200	Drug Delivery	Biocompatibility, reduced toxicity, ability to encapsulate both hydrophobic and hydrophilic drugs	Short circulation time without PEGylation, potential immune response	Doxil (doxorubicin), Onivyde (irinotecan)
Gold Nanoparticles	1-100	Imaging, Drug Delivery, Photothermal Therapy	Excellent optical properties, easy surface modification	Potential toxicity, accumulation in liver and spleen	Nanoshells for photothermal ablation
Iron Oxide Nanoparticles	10-100	MRI Imaging, Hyperthermia Treatment	Magnetic properties, good contrast agents for MRI	Requires surface modification to improve stability and biocompatibility	Ferumoxytol (MRI contrast agent)
Polymeric Nanoparticles	10-1000	Drug Delivery	Controlled drug release, tunable degradation rates	Potential for slow biodegradation, toxicity of some polymers	Paclitaxel-loaded nanoparticles
Quantum Dots	2-10	Imaging	High fluorescence for long-term imaging	Potential heavy metal toxicity, limited clinical use due to safety concerns	Used in preclinical imaging studies

transforming cancer imaging and treatment. Unlike traditional chemotherapy, which harms both healthy and cancerous cells, nanoparticles can target tumors specifically. They enter via the increased permeability and retention (EPR) effect tumor blood vessels and deliver drugs directly to cancer cells, reducing side effects.[18] For example, gold nanoparticles or iron oxide Nanoparticles are commonly utilized as contrast agents. enabling earlier detection of tumours and allowing doctors to monitor how well a treatment is working.[19] Furthermore, the combination of therapy and diagnostics—referred to as theranostics is an exciting development in personalized cancer treatment.[20] The potential of Nanomedicine in cancer treatment is reflected in its rapidly growing market. In 2021, the worldwide Nanomedicine industry was valued at roughly $150 billion and is projected to increase at a compound annual growth rate (CAGR) of 11.9% until 2030.[21] This expansion is propelled by a rising quantity of cancer cases and the demand for more efficient, less toxic therapies. The quantity of clinical trials involving Nanomedicine has also surged in recent years, further demonstrating the promise of this field.[22]

Targeted Drug Delivery Systems

Passive vs. Active Targeting

Nanomedicine targets cancer by directing drugs to tumors, minimizing harm to healthy tissues. The EPR effect enhances drug concentration at the tumor site.[28]

Examples of Targeted Drug Delivery in Clinical Use

Liposomal Formulations (Doxil)

Encapsulation of doxorubicin in liposomes enhances its circulation time and EPR effect, reducing cardiotoxicity. Doxil is used for ovarian and breast cancer, improving progression-free survival.

Antibody-Drug Conjugates (Kadcyla)

Combines trastuzumab with emtansine to target HER2-positive breast cancer cells, reducing toxicity and improving overall survival in clinical trials.

Challenges and Solutions

Immune Response

Nanoparticles may be cleared by the immune system (RES). PEGylation—coating nanoparticles with polyethylene glycol—helps evade immune detection and extends circulation.

Tumor Heterogeneity

Variability in cancer cells limits active targeting. Combining passive and active targeting or developing multifunctional nanoparticles can improve effectiveness.

Advanced Imaging Techniques in Cancer

Role of Nanotechnology in Imaging

Nanotechnology significantly improves cancer imaging by enhancing the resolution and specificity of diagnostic tools. Nanoparticles such as gold nanoparticles, quantum dots, and iron oxide nanoparticles can be designed to interact with imaging modalities, providing better contrast and allowing for more accurate visualization of tumours. These nanoparticles improve the detection of cancer at earlier stages, enabling more precise diagnosis and monitoring of treatment effectiveness.[29]

Common Nanoparticles in Imaging

Gold nanoparticles

Used in computed tomography (CT) and optical imaging, gold nanoparticles provide strong contrast and improve the detection of small tumours.

Quantum dots

These fluorescent nanoparticles are ideal for optical imaging and PET. Their bright fluorescence and stability allow for the precise detection and imaging of cancerous cells. Iron oxide nanoparticles are commonly utilized in

Table: Key Challenges and Solutions in Nano medicine for Cancer Treatment

Challenges	Description	Potential Solutions
Toxicity and Biocompatibility	Risk of nanoparticle accumulation in organs such as the liver and spleen.	Use of biodegradable materials and surface modifications to enhance safety.
Immune System Clearance	Nanoparticles are rapidly eliminated by the reticuloendothelial system. (RES).	PEGylation (coating with polyethylene glycol) to enhance circulation duration.
Scalability of Production	Difficulty in producing nanoparticles consistently on a large scale.	Standardized manufacturing processes and regulatory frameworks.
Tumor Heterogeneity	Variation in cancer cell markers reduces effectiveness of targeted therapy.	Development of multifunctional nanoparticles targeting multiple receptors.
Cost and Commercialization	High production costs limit accessibility and commercial viability.	Focus on cost-effective materials and streamlined production methods.

magnetic resonance imaging (MRI) as contrast agents that enhance image clarity and allow better visualization of tumor boundaries.

Multimodal Imaging Approaches

Combining imaging techniques, such as MRI with fluorescence imaging or PET with CT, is becoming a powerful approach in cancer diagnosis. These multimodal imaging techniques provide complementary information, improving the detection of cancers and allowing real-time monitoring of treatment responses, resulting in more tailored and efficacious treatment methodologies.[30,31]

Nanomedicine in Personalized Cancer Therapy

Theranostics in Cancer Treatment

Theranostics refers to resulting in more tailored and efficacious treatment methodologies, enabling personalized treatment strategies in cancer. By combining these two functions, theranostic nanoparticles allow real-time monitoring of drug delivery, providing doctors with immediate feedback on how a patient's tumour is responding to treatment. This method enhances therapeutic outcomes accuracy then also reduces side things by adjusting the therapy based on the real-time data obtained from diagnostic imaging.[32]

Real-Time Monitoring of Treatment

Using nanomaterial's for real-time monitoring allows physicians to track the delivery of drugs and the response of tumours during the course of therapy. Nanoparticles can be engineered to release therapeutic agents at the tumour site while simultaneously acting as imaging agents. This dual functionality helps to visualize tumour shrinkage or changes in real time through techniques such as MRI, PET, or fluorescence imaging. For example, gold nanoparticles have been utilized in research for medication delivery and simultaneously enhance contrast in imaging techniques like CT and MRI.[33,34]

Nano medicine and Immune Modulation

Immunotherapy with Nanoparticles

Nanoparticles are increasingly being integrated into cancer immunotherapy strategies to enhance the immune system's ability to target and destroy tumors. By improving the delivery of immune-stimulating agents, nanoparticles boost the efficacy of therapies such as cancer vaccines and checkpoint inhibitors. For example, Cancer vaccines use nanoparticles to deliver tumour-specific antigens to immune cells, conditioning the immune system to identify and combat cancer cells. Nanoparticles possess the capability to protect these antigens from degradation and enhance uptake by dendritic cells, improving the vaccine's effectiveness.[35] Checkpoint inhibitors benefit from nanoparticle delivery by enhancing drug stability and targeting, thereby reducing off-target effects and improving immune activation. Nanoparticles can deliver immune checkpoint inhibitors like anti-PD-1/PD-L1 antibodies to tumors more efficiently, ensuring a higher concentration reaches the cancer cells while minimizing toxicity.

Combining Nano medicine with Traditional Immunotherapies

Nano medicine has shown synergistic effects when combined with established immunotherapies, enhancing overall treatment efficacy. Key examples include CAR-T Therapy: Nanoparticles can be used to enhance Chimeric Antigen Receptor T-cell (CAR-T) therapy by improving T-cell targeting and reducing tumours resistance. Nanoparticles can also help to co- administer cytokines or other modulatory substances that boost CAR-T cell persistence and effectiveness.

Checkpoint Inhibitors

Nanoparticles enhance the precision of checkpoint inhibitor therapy by targeting the delivery of antibodies such as anti-PD-1/PD-L1, thus amplifying the immune response against tumours while minimizing systemic side effects.

Cytokine Therapy

Nanoparticles can be designed for delivery cytokines such as IL-2 directly to tumors, helping to modulate the immune environment and recruit more immune cells to the site of the tumor. This targeted delivery system reduces the toxicity commonly associated with cytokine therapy, allowing for higher doses to be administered safely.[36,37]

Regulatory and Safety Considerations

Current Regulatory Framework for Nano medicine

The regulation of Nano medicine-based cancer treatments is governed by entities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These organizations possess established specific guidelines for nanotechnology, focusing on the security, effectiveness, and caliber of Nano medicine products. The FDA has provided guidance through its Nanotechnology Task Force, ensuring that Nano medicine products meet existing regulatory standards for drugs and biologics, with additional scrutiny given to size, behaviour, and interactions of nanoparticles. The EMA also addresses Nano medicine within the context of its broader regulations, requiring thorough assessment of nanomaterial's characteristics, toxicity, and potential long-term effects on patients.[38]

Toxicity and Safety Concerns

Toxicity remains a major concern in the clinical use of nanoparticles. Biocompatibility and bio-distribution need thorough evaluation, as long-term exposure may lead to accumulation in organs like the spleen or liver, with unknown chronic effects. Rigorous preclinical tests are essential to assess their immunogenicity, toxicity, and clearance from the body.[39]

Clinical Translation Challenges

The clinical use of nanomedicine faces challenges like scalability in manufacturing, where producing consistent, high-quality nanoparticles at scale is difficult. High costs, development complexities, and regulatory hurdles further hinder commercialization. Long-term safety concerns also slow adoption, highlighting the need for more research and streamlined approval processes.[40]

FUTURE DIRECTION

Emerging Trends in Nanomedicine

Recent advances in nanoparticle design have led to the use of new materials like biodegradable and biomimetic nanoparticles. Biodegradable nanoparticles can safely break down within the body, lowering long-term toxicity. Meanwhile, biomimetic materials, such as cell membrane-coated nanoparticles, help evade the immune system, enhancing drug delivery effectiveness.[41]

Potential for Artificial Intelligence (AI)

Artificial intelligence is revolutionizing nanomedicine by enabling the design of advanced drug delivery systems. AI models can predict the optimal size, shape, and surface features of nanoparticles for personalized treatment, ensuring precise therapy with fewer side effects. Additionally, AI analyzes extensive datasets to tailor treatments, optimizing patient-specific therapies based on genetic, molecular, and clinical data.[42]

Challenges and Opportunities

Balancing innovation with safety, scalability, and cost remains challenging in nanomedicine. Consistent large-scale production of functional nanoparticles is difficult, and long-term safety concerns persist. However, ongoing research and improved regulatory systems offer opportunities to accelerate the commercialization of these therapies.[43]

CONCLUSION

Nanotechnology has significantly improved cancer treatment by enabling targeted drug delivery and enhancing imaging precision. Nanoparticles help deliver drugs directly to tumors, reducing harm to healthy tissues. Techniques like the Enhanced Permeability and Retention (EPR) effect and ligand-based targeting have boosted the effectiveness of treatments such as Doxil (liposomal doxorubicin) and Kadcyla (antibody-drug conjugate), improving progression-free survival. In imaging, nanoparticles enhance MRI, CT, and PET scan resolution, aiding early cancer detection and precise treatment monitoring. These innovations allow real-time tracking and more personalized therapies The integration of AI in nanoparticle design offers potential for creating smarter, patient-specific therapies by predicting optimal nanoparticle properties, further improving precision and minimizing side effects. Future developments in biodegradable and biomimetic nanoparticles could improve safety by enhancing biocompatibility and reducing long-term toxicity.

Challenges remain, including scalable production, long-term safety, and balancing cost with innovation. Overcoming these issues is vital for bringing Nano medicine to broader clinical use. With the market projected to grow at a CAGR of 11.9% through 2030, the potential to improve cancer survival rates and patient quality of life is promising.

REFERENCES

1. International Agency for Research on Cancer. Latest global cancer data: cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. IARC [Internet]. 2020 Dec 15 [cited 2024 Oct 13]; Available from: https://www.iarc.who.int/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020/
2. World Health Organization. Cancer [Internet]. 2021 [cited 2024 Oct 13]; Available from: https://www.who.int/news-room/fact-sheets/detail/cancer
3. The ASCO Post. GLOBOCAN 2020 Database provides latest global data on cancer burden, cancer deaths [Internet]. 2020 Dec 22 [cited 2024 Oct 13]; Available from: https://ascopost.com/news/december-2020/globocan-2020-database-provides-latest-global-data-on-cancer-burden-cancer-deaths/
4. Massing U, Fuxius S. Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resist Updat. 2000 Jun;3(3):171-177. doi: 10.1054/drup.2000.0138. PMID: 11498382
5. Barenholz Y. Doxil® — the first FDA-approved nano-drug: Lessons learned. J Control Release. 2012;160(2):117-34. DOI: 10.1016/j.jconrel.2012.03.020
6. Michalet X, Pinaud FF, Bentolila LA, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005;307(5709):538-44. DOI: 10.1126/science.1104274
7. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine (Lond). 2007;2(5):681-93. DOI: 10.2217/17435889.2.5.681

8. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26(18):3995-4021. DOI: 10.1016/j.biomaterials.2004.10.012
9. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505-15. DOI: 10.1021/mp800051m
10. Smith AM, Nie S. Semiconductor nanocrystals: structure, properties, and band gap engineering. Acc Chem Res. 2010;43(2):190-200. DOI: 10.1021/ar9001069
11. National Cancer Institute. Radiation therapy for cancer [Internet]. 2021 [cited 2024 Oct 13]; Available from: https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy
12. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004;17(7):484-99. DOI: 10.1002/nbm.924
13. Bawa R, Audette GF, Rubinstein I. Handbook of clinical nanomedicine: Law, business, regulation, safety and risk. CRC Press; 2015. Available from: https://doi.org/10.1201/b19295
14. Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part 1): Products on the market. Int J Nanomedicine. 2014;9:4357-73. DOI: 10.2147/IJN.S46900
15. Ferrari M. Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer. 2005;5(3):161-71. DOI: 10.1038/nrc1566
16. Maeda H, Khatami M. Enhanced permeability and retention effect: A historical perspective. Adv Drug Deliv Rev. 2018;119:3-4. DOI: 10.1016/j.addr.2017.10.017
17. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60. DOI: 10.1038/nnano.2007.387
18. Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys. 2003;36(13) DOI: 10.1088/0022-3727/36/13/201
19. Dreaden EC, Austin LA, Mackey MA, El-Sayed MA. Size matters: Gold nanoparticles in targeted cancer drug delivery. Ther Deliv. 2012;3(4):457-78. DOI: 10.4155/tde.12.21
20. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev. 2012;64(13):1394-416. DOI: 10.1016/j.addr.2012.05.001/
21. Allied Market Research. Nanomedicine Market by Modality (Treatments, Diagnostics), Application (Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine): Global Opportunity Analysis and Industry Forecast, 2021–2030. [Internet]. 2021 [cited 2024 Oct 13]; Available from: https://www.alliedmarketresearch.com/nanomedicine-market
22. Ventola CL. Progress in nanomedicine: Approved and investigational nanodrugs. P T. 2017;42(12):742-55. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688411/
23. Olusanya TOB, Haj Ahmad RR, Ibegbu DM, Smith JR, Elkordy AA. Liposomal Drug Delivery Systems and Anticancer Drugs. Molecules. 2018 Apr 14;23(4):907. doi: 10.3390/molecules23040907. PMID: 29662019; PMCID: PMC6017847. https://pubmed.ncbi.nlm.nih.gov/29662019/
24. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine (Lond). 2007;2(5):681-93. Available from: https://doi.org/10.2217/17435889.2.5.681
25. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26(18):3995-4021. Available from: https://doi.org/10.1016/j.biomaterials.2004.10.012
26. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505-15. Available from: https://doi.org/10.1021/mp800051m
27. Michalet X, Pinaud FF, Bentolila LA, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005;307(5709):538-44. Available from: https://doi.org/10.1126/science.1104274
28. Maeda H, Khatami M. Enhanced permeability and retention effect: A historical perspective. Adv Drug Deliv Rev. 2018;119:3-4. DOI: 10.1016/j.addr.2017.10.017
29. Burda C, Basilion JP. Recent Development of Gold Nanoparticles as Contrast Agents for Cancer Diagnosis. Cancers (Basel). 2021;13(8):1825. DOI: 10.3390/cancers13081825.
30. Sztandera K, Gorzkiewicz M, Klajnert-Maculewicz B. Gold nanoparticles in cancer treatment. Mol Cancer. 2019;18(1):129. DOI: 10.1186/s12943-019-1056-6.
31. Radiolabeled Nanoparticles for Multimodal Cancer Imaging and Theranostic Applications. Cancer Imaging. 2020;20(1):31. DOI: 10.1186/s40644-020-00316-7.
32. Burda C, Basilion JP. Recent Development of Gold Nanoparticles as Contrast Agents for Cancer Diagnosis. Cancers (Basel). 2021;13(8):1825. DOI: 10.3390/cancers13081825.
33. Sztandera K, Gorzkiewicz M, Klajnert-Maculewicz B. Gold nanoparticles in cancer treatment. Mol Cancer. 2019;18(1):129. DOI: 10.1186/s12943-019-1056-6.
34. Radiolabeled Nanoparticles for Multimodal Cancer Imaging and Theranostic Applications. Cancer Imaging. 2020;20(1):31. DOI: 10.1186/s40644-020-00316-7.
35. Burda C, Basilion JP. Recent Development of Gold Nanoparticles as Contrast Agents for Cancer Diagnosis. Cancers (Basel). 2021;13(8):1825. DOI: 10.3390/cancers13081825.
36. Sztandera K, Gorzkiewicz M, Klajnert-Maculewicz B. Gold nanoparticles in cancer treatment. Mol Cancer. 2019;18(1):129. DOI: 10.1186/s12943-019-1056-6.
37. Radiolabeled Nanoparticles for Multimodal Cancer Imaging and Theranostic Applications. Cancer Imaging. 2020;20(1):31. DOI: 10.1186/s40644-020-00316-7.
38. Food and Drug Administration. Nanotechnology Task Force Report 2020 [Internet]. Available from: https://www.fda.gov/science-research/nanotechnology-programs-fda
39. European Medicines Agency. Reflection paper on nanotechnology-based medicinal products for human use

[Internet]. 2021 [cited 2024 Oct 13]. Available from: https://www.ema.europa.eu/en/nanotechnology-based-medicinal-products
40. Raj S, Khurana S, Choudhury A, et al. Specific targeting cancer therapy using nanomedicine. Molecules. 2022;27(2):123. DOI: 10.3390/molecules27020576
41. Burda C, Basilion JP. Recent Development of Gold Nanoparticles as Contrast Agents for Cancer Diagnosis. Cancers (Basel). 2021;13(8):1825. DOI: 10.3390/cancers13081825.
42. Sztandera K, Gorzkiewicz M, Klajnert-Maculewicz B. Gold nanoparticles in cancer treatment. Mol Cancer. 2019;18(1):129. DOI: 10.1186/s12943-019-1056-6.
43. Raj S, Khurana S, Choudhury A, et al. Specific targeting cancer therapy using nanomedicine. Molecules. 2022;27(2):123. DOI: 10.3390/molecules27020576.